PREVENTION OF CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS

被引：22

作者：

WINSTON, DJ

机构：

[1] Department of Medicine, UCLA Medical Center, Los Angeles, CA

来源：

LANCET | 1995年 / 346卷 / 8987期

关键词：

D O I：

10.1016/S0140-6736(95)92401-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1380 / 1381

页数：2

共 13 条

[1]

BOECKH M, 1994, 34TH INT C ANT AG CH, V7

[2] CYTOMEGALOVIRUS IMMUNE GLOBULIN AND SERONEGATIVE BLOOD PRODUCTS TO PREVENT PRIMARY CYTOMEGALOVIRUS-INFECTION AFTER MARROW TRANSPLANTATION [J].

BOWDEN, RA ;

SAYERS, M ;

FLOURNOY, N ;

NEWTON, B ;

BANAJI, M ;

THOMAS, ED ;

MEYERS, JD .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (16) :1006-1010

[3] GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT [J].

GOODRICH, JM ;

BOWDEN, RA ;

FISHER, L ;

KELLER, C ;

SCHOCH, G ;

MEYERS, JD .

ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :173-178

[4] EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].

GOODRICH, JM ;

MORI, M ;

GLEAVES, CA ;

DUMOND, C ;

CAYS, M ;

EBELING, DF ;

BUHLES, WC ;

DEARMOND, B ;

MEYERS, JD .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1601-1607

[5] PREEMPTIVE GANCICLOVIR THERAPY TO PREVENT CYTOMEGALOVIRUS DISEASE IN CYTOMEGALOVIRUS ANTIBODY-POSITIVE RENAL-TRANSPLANT RECIPIENTS - A RANDOMIZED CONTROLLED TRIAL [J].

HIBBERD, PL ;

TOLKOFFRUBIN, NE ;

CONTI, D ;

STUART, F ;

THISTLETHWAITE, JR ;

NEYLAN, JF ;

SNYDMAN, DR ;

FREEMAN, R ;

LORBER, MI ;

RUBIN, RH .

ANNALS OF INTERNAL MEDICINE, 1995, 123 (01) :18-26

[6]

MARTIN M, 1994, TRANSPLANTATION, V58, P225

[7] IMPACT OF LONG-TERM ACYCLOVIR ON CYTOMEGALOVIRUS-INFECTION AND SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].

PRENTICE, HG ;

GLUCKMAN, E ;

POWLES, RL ;

LJUNGMAN, P ;

MILPIED, NJ ;

RANADA, JMF ;

MANDELLI, F ;

KHO, P ;

KENNEDY, L ;

BELL, AR ;

HAMON, MD ;

COUMAR, A ;

HIRSCH, I ;

HANRAHAN, A ;

BURNETT, A ;

RUSSELL, N ;

HUNTER, A ;

CAHN, JY ;

FLESCH, M ;

FIERE, D ;

TIGAUD, J ;

ASHCAN, J ;

ARCESE, W ;

DINUCCI, G ;

GENTILE, G ;

DELAURENZI, A ;

PACILLI, L ;

ROSSIFERRINI, P ;

BOSI, A ;

MARTELLI, M ;

AVERSA, F ;

FELICINI, R ;

TURA, S ;

ROSTI, G ;

BERLARDINELLI, AR ;

BERNASCONI, C ;

ALLESSANDRINO, E ;

LUCARELLI, G ;

GALIMBERTI, M ;

KOLB, JH ;

CAMERA, R ;

BEESLEY, K ;

FIDDIAN, AP ;

GEFFRIER, C ;

PAPARATTI, U ;

PARKE, A ;

USAN, L .

LANCET, 1994, 343 (8900) :749-753

[8] HIGH-DOSE ACYCLOVIR COMPARED WITH SHORT-COURSE PREEMPTIVE GANCICLOVIR THERAPY TO PREVENT CYTOMEGALOVIRUS DISEASE IN LIVER-TRANSPLANT RECIPIENTS - A RANDOMIZED TRIAL [J].

SINGH, N ;

YU, VL ;

MIELES, L ;

WAGENER, MM ;

MINER, RC ;

GAYOWSKI, T .

ANNALS OF INTERNAL MEDICINE, 1994, 120 (05) :375-381

[9] CYTOMEGALOVIRUS IMMUNE GLOBULIN PROPHYLAXIS IN LIVER-TRANSPLANTATION - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

SNYDMAN, DR ;

WERNER, BG ;

DOUGHERTY, NN ;

GRIFFITH, J ;

RUBIN, RH ;

DIENSTAG, JL ;

ROHRER, RH ;

FREEMAN, R ;

JENKINS, R ;

LEWIS, D ;

HAMMER, S ;

OROURKE, E ;

GRADY, GF ;

FAWAZ, K ;

KAPLAN, MM ;

HOFFMAN, MA ;

KATZ, AT ;

DORAN, M .

ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :984-991

[10] GANCICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS-INFECTION AND DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS - RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL [J].

WINSTON, DJ ;

HO, WG ;

BARTONI, K ;

DUMOND, C ;

EBELING, DF ;

BUHLES, WC ;

CHAMPLIN, RE .

ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :179-184

← 1 2 →